Terms: = Kidney tumors AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
16 results:
1. Case report: Sagliker syndrome in the patient with recurrent tertiary hyperparathyroidism due to intrathyroidal parathyroid carcinoma.
Salimkhanov R; Bondarenko E; Eremkina A; Bibik E; Kim E; Begova K; Kim I; Kuznetsov S; Mokrysheva N
Front Endocrinol (Lausanne); 2023; 14():1292993. PubMed ID: 38250739
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract] [Full Text] [Related]
3. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
Grahn A; Eisfeldt J; Malm C; Foroughi Asl H; Jaremko G; Tham E; Brehmer M
BJU Int; 2022 Jul; 130(1):92-101. PubMed ID: 34375486
[TBL] [Abstract] [Full Text] [Related]
4. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
Sfakianos JP; Gul Z; Shariat SF; Matin SF; Daneshmand S; Plimack E; Lerner S; Roupret M; Pal S
Eur Urol Oncol; 2021 Apr; 4(2):170-179. PubMed ID: 33386276
[TBL] [Abstract] [Full Text] [Related]
5. Targetable gene fusions and aberrations in genitourinary oncology.
Pederzoli F; Bandini M; Marandino L; Ali SM; Madison R; Chung J; Ross JS; Necchi A
Nat Rev Urol; 2020 Nov; 17(11):613-625. PubMed ID: 33046892
[TBL] [Abstract] [Full Text] [Related]
6. treatment outcomes of percutaneous radiofrequency ablation versus adrenalectomy for adrenal metastases: a retrospective comparative study.
Liu B; Mo C; Wang W; Ye J; Jiang C; Xie X; Huang J; Huang G; Long H; Xie X
J Endocrinol Invest; 2020 Sep; 43(9):1249-1257. PubMed ID: 32166699
[TBL] [Abstract] [Full Text] [Related]
7. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated fgfr3 signaling.
Robinson BD; Vlachostergios PJ; Bhinder B; Liu W; Li K; Moss TJ; Bareja R; Park K; Tavassoli P; Cyrta J; Tagawa ST; Nanus DM; Beltran H; Molina AM; Khani F; Miguel Mosquera J; Xylinas E; Shariat SF; Scherr DS; Rubin MA; Lerner SP; Matin SF; Elemento O; Faltas BM
Nat Commun; 2019 Jul; 10(1):2977. PubMed ID: 31278255
[TBL] [Abstract] [Full Text] [Related]
8. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
9. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Bellmunt J; Lalani AA; Jacobus S; Wankowicz SA; Polacek L; Takeda DY; Harshman LC; Wagle N; Moreno I; Lundgren K; Bossé D; Van Allen EM; Choueiri TK; Rosenberg JE
Br J Cancer; 2018 Sep; 119(6):707-712. PubMed ID: 30220708
[TBL] [Abstract] [Full Text] [Related]
10. An fgfr3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.
Bagrodia A; Audenet F; Pietzak EJ; Kim K; Murray KS; Cha EK; Sfakianos JP; Iyer G; Singla N; Arcila M; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol Focus; 2019 May; 5(3):365-368. PubMed ID: 29396293
[TBL] [Abstract] [Full Text] [Related]
12. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract] [Full Text] [Related]
13. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent fgfr3 mutation in Han Chinese patients.
Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
[TBL] [Abstract] [Full Text] [Related]
14. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract] [Full Text] [Related]
15. Biomolecular characterization of adrenal gland tumors by means of SR-FTIR.
Dudala J; Bialas M; Surowka A; Bereza-Buziak M; Hubalewska-Dydejczyk A; Budzynski A; Pedziwiatr M; Kolodziej M; Wehbe K; Lankosz M
Analyst; 2015 Apr; 140(7):2101-6. PubMed ID: 25519296
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of molecular cytogenetic changes in metastatic renal cell carcinoma in the setting of everolimus treatment: a pilot project.
Caldwell IR; Oei P; Ng D; Caudwell B; Fong PC; Broom RJ
Clin Genitourin Cancer; 2014 Aug; 12(4):256-61. PubMed ID: 24524969
[TBL] [Abstract] [Full Text] [Related]
